About EndeavorRx
EndeavorRx is the first FDA-approved prescription treatment delivered through a video game, designed for children ages 8-17 with inattentive or combined-type ADHD. Created by world-class neuroscientists and award-winning game designers, the digital therapeutic uses sensory stimuli and motor challenges to target brain areas key to attention function. Kids are challenged to multitask and ignore distractions by navigating courses, collecting targets, and avoiding obstacles. The treatment protocol involves 25 minutes of play per day, 5 days a week, for 4 weeks. In clinical trials with over 600 children, roughly half of parents reported clinically meaningful improvement in their child's daily impairments after one month.
Best For
- • Child psychiatrists
- • pediatric neurologists
- • and developmental pediatricians treating children ages 8-17 with ADHD who may benefit from non-pharmacological attention training
Not Ideal For
- • Practices not treating pediatric ADHD patients
- • or patients with photosensitive epilepsy or conditions that preclude video game use
Pricing
Contact for pricing
Compliance & Security
Always verify compliance directly with the vendor.
Target Audience
Roles
Settings
Related Tools
Akili EndeavorOTC
FDA-cleared OTC video game for adult ADHD
Akili Interactive (EndeavorRx, EndeavorOTC)
First FDA-cleared video game digital therapeutic for ADHD in children and adults.
Big Health (Sleepio, Daylight)
First FDA-cleared DTx for anxiety (DaylightRx) and insomnia (SleepioRx) with Medicare coverage.
Blueprint
Free EHR with AI assistant and measurement-based care for therapists.